Additionally, we used the external database Oncomine to analyze the expression of IGF2BP3 in AML patients/samples, and the expression of IGF2BP3 was observed to be upregulated compared with that in the normal controls in the Andersson Leukemia and Haferlach Leukemia cohorts (Supplementary Fig. 2a–c). This evidence concerns the gene IGF2BP3 and acute myeloid leukemia.